Peter R. Rossing

Peter R. Rossing

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 707 publications

Leave no one behind: optimizing kidney protection in type 1 diabetes.

Leave no one behind: optimizing kidney protection in type 1 diabetes.

Journal: Nature reviews. Nephrology
Published: August 13, 2026

Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes.

Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes.

Journal: Nature reviews. Nephrology
Published: August 06, 2026

Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate.

Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: July 03, 2026

Corrigendum to "Association between interleukin-6, suPAR, and hsCRP with subclinical left ventricular dysfunction in type 1 diabetes: The Thousand & 1 study" [Diabetes Res. Clin. Pract. 222 (2025) 112071].

Corrigendum to "Association between interleukin-6, suPAR, and hsCRP with subclinical left ventricular dysfunction in type 1 diabetes: The Thousand & 1 study" [Diabetes Res. Clin. Pract. 222 (2025) 112071].

Journal: Diabetes research and clinical practice
Published: July 01, 2026

GLP-1 receptor agonists in patients with Type 2 diabetes: cardiorenal protection versus ocular safety.

GLP-1 receptor agonists in patients with Type 2 diabetes: cardiorenal protection versus ocular safety.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: June 18, 2026

Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.

Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.

Journal: Hypertension (Dallas, Tex. : 1979)
Published: June 05, 2026

Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages: Post Hoc Analysis of the FIDELITY Randomized Clinical Trials.

Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages: Post Hoc Analysis of the FIDELITY Randomized Clinical Trials.

Journal: JAMA cardiology
Published: June 03, 2026

Complication rates of 16- and 18-gauge needles for native kidney biopsies: a systematic review and proportional meta-analysis.

Complication rates of 16- and 18-gauge needles for native kidney biopsies: a systematic review and proportional meta-analysis.

Journal: Renal failure
Published: May 25, 2026

The HFpEF-ABA Score, Incident Heart Failure, and Finerenone in Chronic Kidney Disease with Type 2 Diabetes.

The HFpEF-ABA Score, Incident Heart Failure, and Finerenone in Chronic Kidney Disease with Type 2 Diabetes.

Journal: Journal of cardiac failure
Published: May 21, 2026

Efficacy and safety of dapagliflozin in patients receiving dialysis: a post-hoc analysis of the DAPA-CKD trial.

Efficacy and safety of dapagliflozin in patients receiving dialysis: a post-hoc analysis of the DAPA-CKD trial.

Journal: Clinical kidney journal
Published: May 20, 2026

Response to Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.

Response to Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.

Journal: Diabetes care
Published: May 20, 2026

Serum Lipidomics Profiling Identify Novel Biomarkers of Distal Symmetrical Polyneuropathy in Type 1 Diabetes.

Serum Lipidomics Profiling Identify Novel Biomarkers of Distal Symmetrical Polyneuropathy in Type 1 Diabetes.

Journal: Diabetes, obesity & metabolism
Published: May 19, 2026
Showing 1-12 of 707

Last Updated: 09/26/2026